Incidence, clinical characteristics, and management of psoriasis induced by Anti-TNF therapy in patients with inflammatory bowel disease: A nationwide cohort study

Inflammatory Bowel Diseases

Volumn 22, Issue 4, 2016, Pages 894-901

  Guerra, Iván ^a   Pérez Jeldres, Tamara ^b,c   Iborra, Marisa ^c,d   Algaba, Alicia ^a   Monfort, David ^e   Calvet, Xavier ^c,f   Chaparro, María ^c,g   Mañosa, Miriam ^c,h   Hinojosa, Esther ⁱ   Minguez, Miguel ^j   Ortiz De Zarate, Jone ^k   Márquez, Lucía ^l   Prieto, Vanessa ^m   García Sánchez, Valle ⁿ   Guardiola, Jordi ^o   Rodriguez, G Esther ^p   Martín Arranz, María Dolores ^q   García Tercero, Iván ^r   Sicilia, Beatriz ^s   Masedo, Ángeles ^t   Lorente, Rufo ^u   Rivero, Montserrat ^v   Fernández Salazar, Luis ^w   Gutiérrez, Ana ^c,x   Van Domselaar, Manuel ^y   López Sanromán, Antonio ^z   Ber, Yolanda ^c,aa   García Sepulcre, Marifé ^ab   Ramos, Laura ^ac   Bermejo, Fernando ^a   Gisbert, Javier P ^c,g   more..

^a HOSPITAL UNIVERSITARIO DE FUENLABRADA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d HOSPITAL UNIVERSITARIO LA FE   (Spain)

^e Brain   (Spain)

^f Hospital Universitari Parc Taulí   (Spain)

^g HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^h HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

ⁱ HOSPITAL DE MANISES   (Spain)

^j UNIVERSITY OF VALENCIA   (Spain)

^k HOSPITAL DE BASURTO   (Spain)

^l HOSPITAL DEL MAR   (Spain)

^m HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

ⁿ UNIVERSITY OF CÓRDOBA   (Spain)

^o HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^p HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

^q HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^r HOSPITAL UNIVERSITARIO SANTA LUCÍA   (Spain)

^s HOSPITAL UNIVERSITARIO DE BURGOS   (Spain)

^t HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^u HOSPITAL GENERAL UNIVERSITARIO DE CIUDAD REAL   (Spain)

^v HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^w HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

^x HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^y HOSPITAL UNIVERSITARIO DE TORREJÓN   (Spain)

^z HOSPITAL RAMÓN Y CAJAL   (Spain)

^aa HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^ab HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

^ac HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

more..

Author keywords

adalimumab; anti TNF; Crohn's disease; inflammatory bowel disease; infliximab; psoriasis; side effects; ulcerative colitis

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; USTEKINUMAB; ANTIINFLAMMATORY AGENT; GASTROINTESTINAL AGENT; TUMOR NECROSIS FACTOR;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; HUMAN; INCIDENCE; INFLAMMATORY BOWEL DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSORIASIS; PUSTULOSIS PALMOPLANTARIS; RECURRENT DISEASE; SEX DIFFERENCE; SKIN BIOPSY; SMOKING; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; CASE CONTROL STUDY; CLINICAL TRIAL; COLITIS, ULCERATIVE; COMPARATIVE STUDY; CROHN DISEASE; FOLLOW UP; MULTICENTER STUDY; PATHOLOGY; PROGNOSIS; SPAIN; TREATMENT WITHDRAWAL;

ADALIMUMAB; ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS; CASE-CONTROL STUDIES; COHORT STUDIES; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL AGENTS; HUMANS; INCIDENCE; INFLIXIMAB; MALE; PROGNOSIS; PSORIASIS; SPAIN; TUMOR NECROSIS FACTOR-ALPHA; WITHHOLDING TREATMENT;

EID: 84962288522     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000757     Document Type: Article

References (31)

1. Spoettl T, Hausmann M, Klebl F, et al. Serum soluble TNF receptor I and II levels correlate with disease activity in IBD patients. Inflamm Bowel Dis. 2007;13:727-732.
2. de Gannes GC, Ghoreishi M, Pope J, et al. Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions. Arch Dermatol. 2007;143:223-231.
3. Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, et al. Long-Term complications, extraintestinal manifestations, and mortality in adult Crohn?s disease in population-based cohorts. Inflamm Bowel Dis. 2011;17:471-478.
4. Park JJ, Lee SC. A case of tumor necrosis factor-Alpha inhibitors-induced pustular psoriasis. Ann Dermatol. 2010;22:212-215.
5. Li WQ, Han JL, Chan AT, et al. Psoriasis, psoriatic arthritis and increased risk of incident Crohn?s disease in us women. Ann Rheum Dis. 2013;72: 1200-1205.
6. Lolli E, Saraceno R, Calabrese E, et al. Psoriasis phenotype in inflammatory bowel disease: a case-control prospective study. J Crohns Colitis. 2015.
7. Guerra I, Gisbert JP. Onset of psoriasis in patients with inflammatory bowel disease treated with anti-TNF agents. Expert Rev Gastroenterol Hepatol. 2013;7:41-48.
8. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl. 1989;170:2-6; discussion 16-9.
9. Rahier JF, Buche S, Peyrin-Biroulet L, et al. Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-Tumor necrosis factor therapy. Clin Gastroenterol Hepatol. 2010;8:1048-1055.
10. Guerra I, Algaba A, Perez-Calle JL, et al. Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: a report of 21 cases. J Crohns Colitis. 2012;6:518-523.
11. Cullen G, Kroshinsky D, Cheifetz AS, et al. Psoriasis associated with antitumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature. Aliment Pharmacol Ther. 2011;34:1318-1327.
12. Denadai R, Teixeira FV, Steinwurz F, et al. Induction or exacerbation of psoriatic lesions during anti-TNF-Alpha therapy for inflammatory bowel disease: a systematic literature review based on 222 cases. J Crohns Colitis. 2013;7:517-524.
13. Amur S, Parekh A, Mummaneni P. Sex differences and genomics in autoimmune diseases. J Autoimmun. 2012;38:J254-J265.
14. Armstrong AW, Harskamp CT, Dhillon JS, et al. Psoriasis and smoking: a systematic review and meta-Analysis. Br J Dermatol. 2014;170: 304-314.
15. Tillack C, Ehmann LM, Friedrich M, et al. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-gamma-Expressing TH1 cells and IL-17A/IL-22-Expressing TH17 cells and respond to anti-IL-12/IL-23 antibody treatment. Gut. 2014;63:567-577.
16. Pugliese D, Ferraro PM, Marzo M, et al. P586. Paradoxical psoriasis in a large cohort of IBD patients treated with anti-TNF alpha: 5 years-followup study. J Crohns Colitis. 2015;9:S373-S374.
17. Wlodarczyk M, Sobolewska A, Wojcik B, et al. Correlations between skin lesions induced by anti-Tumor necrosis factor-Alpha and selected cytokines in Crohn?s disease patients. World J Gastroenterol. 2014;20:7019-7026.
18. Cargill M, Schrodi SJ, Chang M, et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasisrisk genes. Am J Hum Genet. 2007;80:273-290.
19. Glas J, Seiderer J, Wetzke M, et al. rs1004819 is the main diseaseassociated IL23R variant in german Crohn?s disease patients: combined analysis of IL23R, CARD15, and OCTN1/2 variants. PLoS One. 2007;2: e819.
20. Cleynen I, Vermeire S. Paradoxical inflammation induced by anti-TNF agents in patients with IBD. Nat Rev Gastroenterol Hepatol. 2012;9: 496-503.
21. Afzali A, Wheat CL, Hu JK, et al. The association of psoriasiform rash with anti-Tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: a single academic center case series. J Crohns Colitis. 2014;8: 480-488.
22. Malkonen T, Wikstrom A, Heiskanen K, et al. Skin reactions during anti-TNFa therapy for pediatric inflammatory bowel disease: a 2-year prospective study. Inflamm Bowel Dis. 2014;20:1309-1315.
23. Denadai R, Teixeira FV, Saad-Hossne R. The onset of psoriasis during the treatment of inflammatory bowel diseases with infliximab: should biological therapy be suspended?. Arq Gastroenterol. 2012;49:172-176.
24. Fiorino G, Danese S, Pariente B, et al. Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF-Alpha agents. Autoimmun Rev. 2014;13:15-19.
25. Navarro R, Dauden E. Clinical management of paradoxical psoriasiform reactions during TNF-A therapy. Actas Dermosifiliogr. 2014;105: 752-761.
26. George LA, Gadani A, Cross RK, et al. Psoriasiform skin lesions are caused by anti-TNF agents used for the treatment of inflammatory bowel disease. Dig Dis Sci. 2015.
27. Feuerstein JD, Cheifetz AS. Miscellaneous adverse events with biologic agents (excludes infection and malignancy). Gastroenterol Clin North Am. 2014;43:543-563.
28. Iborra M, Beltran B, Bastida G, et al. Infliximab and adalimumab-induced psoriasis in Crohn?s disease: a paradoxical side effect. J Crohns Colitis. 2011;5:157-161.
29. Buisson A, Cuny JF, Barbaud A, et al. Methotrexate for psoriasiform lesions associated with anti-Tumour necrosis factor therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2012;35:1175-1180.
30. Khanna R, Preiss JC, MacDonald JK, et al. Anti-IL-12/23p40 antibodies for induction of remission in Crohn?s disease. Cochrane Database Syst Rev. 2015;5:CD007572.
31. Niess JH, Danese S. Anti-TNF and skin inflammation in IBD: a new paradox in gastroenterology?. Gut. 2014;63:533-535.